Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1623 1627
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18134539 | METHOD OF PREVENTING KIDNEY INJURY DISRUPTION OF INTESTINAL LYMPHATICS | Final Rejection | Vanderbilt University |
| 19198257 | FATTY ACID COMPOSITIONS | Final Rejection | Fera Diagnostics and Biologicals Corp. |
| 17701051 | TREATMENT OF FERROPTOSIS | Non-Final OA | Nacuity Pharmaceuticals, Inc. |
| 16433298 | TREATMENT OF MIGRAINE | Final Rejection | Allergan Pharmaceuticals International Limited |
| 15765960 | COMPOUNDS AND COMPOSITIONS HAVING KNOCK-DOWN OR BLOOD FEED INHIBITION ACTIVITY AGAINST INSECT PESTS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18845088 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | Non-Final OA | Mindstate Design Labs, Inc. |
| 18038821 | SIRTUIN 6 ACTIVATOR | Non-Final OA | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 18285409 | COMPOSITION FOR INCREASING RED BLOOD CELLS AND/OR HEMOGLOBIN | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 17058046 | METHODS FOR TREATING SPINAL CORD INJURY | Final Rejection | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 18567435 | FORMULATION CONTAINING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | Non-Final OA | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 18581224 | COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE | Non-Final OA | Schedule 1 Therapeutics, Inc. |
| 18275965 | Dosing Protocols for Administering Deuterated Arachidonic Acid or a Prodrug Thereof | Non-Final OA | BioJiva LLC |
| 18549622 | BELVARAFENIB FOR USE IN TREATMENT OF BRAIN CANCERS | Non-Final OA | Hanmi Pharm. Co., Ltd. |
| 18568899 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | Non-Final OA | Scorpion Therapeutics, Inc. |
| 18287096 | FORMULATIONS OF CANNABINOIDS | Non-Final OA | ADD Advanced Drug Delivery Technologies LTD. |
| 17786175 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | Non-Final OA | AGENEBIO, INC. |
| 18277746 | SALT AND CRYSTAL FORMS OF AN HMOX1 INDUCER | Non-Final OA | MITOBRIDGE INC. |
| 16967824 | Treatment Of Patients With Classic Fabry Disease | Final Rejection | Amicus Therapeutics, Inc. |
| 18273418 | PHENOL DERIVATIVE AND APPLICATION THEREOF IN MEDICAMENTS | Non-Final OA | HINYE PHARMACEUTICAL CO., LTD. |
| 18265525 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | Non-Final OA | Tonix Pharma Limited |
| 18328682 | ADJUNCTIVE THERAPY FOR DEPRESSION | Non-Final OA | ANeuroTech BV |
| 18038401 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | Non-Final OA | Crestone, Inc. |
| 18200148 | Methods for the Prevention and Treatment of Hearing Loss | Non-Final OA | Ting Therapeutics, Inc. |
| 18006817 | Products for Treating the JNCL Disease | Non-Final OA | University College Cardiff Consultants Limited |
| 18003153 | TREATMENT OF SYSTEMIC IMMUNE ACTIVATION SYNDROMES | Non-Final OA | TRANQUIS THERAPEUTICS, INC. |
| 18007807 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Final Rejection | KINETA, INC. |
| 17673845 | COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF | Non-Final OA | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. |
| 17916191 | NEW COMPOSITIONS FOR ORAL OR NASAL USE | Non-Final OA | md&c Creative Maison SA |
| 17076493 | METHOD OF ADMINISTERING BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) | Non-Final OA | Metabolic Technologies, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy